Leerink Partnrs Has Negative Outlook of PTCT FY2026 Earnings

PTC Therapeutics, Inc. (NASDAQ:PTCT) – Research analysts at Leerink Partnrs dropped their FY2026 EPS estimates for PTC Therapeutics in a report issued on Sunday, November 16th. Leerink Partnrs analyst J. Schwartz now forecasts that the biopharmaceutical company will post earnings of ($2.42) per share for the year, down from their previous estimate of ($1.66). The consensus estimate for PTC Therapeutics’ current full-year earnings is ($4.52) per share.

A number of other research analysts have also recently commented on the stock. Robert W. Baird set a $70.00 price target on shares of PTC Therapeutics in a research report on Friday, August 8th. Jefferies Financial Group increased their target price on shares of PTC Therapeutics from $63.00 to $77.00 and gave the company a “buy” rating in a report on Tuesday, October 28th. Bank of America decreased their target price on shares of PTC Therapeutics from $82.00 to $76.00 and set a “buy” rating on the stock in a research report on Wednesday, August 20th. Cantor Fitzgerald reissued an “overweight” rating and issued a $118.00 price target on shares of PTC Therapeutics in a research note on Wednesday, September 3rd. Finally, Truist Financial raised their price objective on PTC Therapeutics from $80.00 to $86.00 and gave the company a “buy” rating in a research note on Tuesday, July 29th. Ten analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $75.40.

PTC Therapeutics Trading Up 1.4%

Shares of NASDAQ PTCT opened at $76.69 on Wednesday. The stock’s 50-day moving average is $66.02 and its 200 day moving average is $54.90. The stock has a market cap of $6.16 billion, a price-to-earnings ratio of 11.00 and a beta of 0.60. PTC Therapeutics has a 1-year low of $35.95 and a 1-year high of $77.46.

PTC Therapeutics (NASDAQ:PTCT) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.19) by $1.39. PTC Therapeutics had a negative return on equity of 106.31% and a net margin of 35.65%.The firm had revenue of $211.01 million during the quarter, compared to analyst estimates of $177.42 million. During the same quarter in the previous year, the company posted ($1.39) earnings per share. The company’s revenue was up 7.2% compared to the same quarter last year. PTC Therapeutics has set its FY 2025 guidance at EPS.

Institutional Trading of PTC Therapeutics

Several large investors have recently added to or reduced their stakes in PTCT. CANADA LIFE ASSURANCE Co raised its holdings in PTC Therapeutics by 55.9% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 33,984 shares of the biopharmaceutical company’s stock worth $2,060,000 after purchasing an additional 12,191 shares in the last quarter. Woodline Partners LP purchased a new stake in PTC Therapeutics in the third quarter worth about $6,481,000. Qube Research & Technologies Ltd grew its holdings in shares of PTC Therapeutics by 27.4% during the 3rd quarter. Qube Research & Technologies Ltd now owns 430,934 shares of the biopharmaceutical company’s stock worth $26,446,000 after acquiring an additional 92,771 shares during the period. Palo Alto Investors LP raised its position in shares of PTC Therapeutics by 112.2% in the 3rd quarter. Palo Alto Investors LP now owns 862,613 shares of the biopharmaceutical company’s stock worth $52,939,000 after acquiring an additional 456,144 shares in the last quarter. Finally, Parkman Healthcare Partners LLC lifted its stake in shares of PTC Therapeutics by 11.4% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 202,363 shares of the biopharmaceutical company’s stock valued at $12,419,000 after purchasing an additional 20,720 shares during the period.

Insider Activity

In other news, Director Emma Reeve sold 7,333 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $74.50, for a total transaction of $546,308.50. Following the completion of the transaction, the director directly owned 6,666 shares of the company’s stock, valued at approximately $496,617. This represents a 52.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Mark Elliott Boulding sold 3,375 shares of the firm’s stock in a transaction dated Tuesday, October 7th. The stock was sold at an average price of $63.43, for a total value of $214,076.25. Following the completion of the sale, the vice president directly owned 103,901 shares in the company, valued at $6,590,440.43. The trade was a 3.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 261,995 shares of company stock worth $16,547,129 in the last quarter. Insiders own 5.50% of the company’s stock.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.